How comparing works here
How do I compare two companies?
Type the tickers into the box above — up to five at once. Every row is read from the companies' own annual filings, so a comparison shows the same measure computed the same way for each of them rather than whatever each company chose to highlight.
Can I compare an ETF with a stock?
Yes, and the table changes to suit. Two funds are compared on cost, income, spread and record, because revenue growth and debt mean nothing for a fund. A fund against a company shows only what both of them have.
Side by side
Compare
Put up to 4 companies, funds, commodities or coins next to each other — health, valuation, growth and performance.
Every row is computed the same way for every column, from each company's own annual filing, so a comparison is not a collection of whichever figures each of them chose to put in a press release. Funds are compared on what a fund is actually judged on: cost, income, spread and record.
Relative performance
Rebased so every symbol starts at 0%
Loading price history…
Side by side
Latest annual figures from each company's filings
| Metric | CRLCHARLES RIVER LABORATORIES INTERNATIONAL, INC. | ILMNILLUMINA, INC. | MTDMETTLER TOLEDO INTERNATIONAL INC/ | WSTWEST PHARMACEUTICAL SERVICES INC | Median of the restexcluding CRL |
|---|---|---|---|---|---|
| Type | Company | Company | Company | Company | |
| Price | $344.87▲ 29.42 (9.33%) | $282.86▲ 14.93 (5.57%) | $1677.94▲ 43.93 (2.69%) | $394.03▲ 0.55 (0.14%) | |
| Health scoreComposite of profitability, growth, debt and accounting quality. | 2.0/10 | 6.0/10 | 8.7/10 | 9.0/10 | 8.7/10 |
| Market value | $16.97B | $43.28B | $34.16B | $28.37B | |
| Revenue | $4.02B | $4.34B | $4.03B | $3.07B | |
| Profit | -$144.3M | $850.0M | $869.2M | $493.7M | |
| Revenue growthChange in sales versus the prior year. | -0.9% | -0.7% | 4.0% | 6.3% | 4.0% |
| Gross marginShare of sales left after the direct cost of producing them. | — | 66.1% | 59.4% | 35.9% | 59.4% |
| Operating marginShare of sales left after running the business, before interest and tax. | 0.6% | 18.6% | — | 19.0% | 18.8% |
| Profit marginProfit kept from each dollar of sales. | -3.6% | 19.6% | 21.6% | 16.1% | 19.6% |
| Free cash flow marginCash left after capital spending, as a share of sales. | 12.9% | 21.4% | 21.1% | 15.3% | 21.1% |
| Return on equityProfit against the owners' stake in the company. | -4.6% | 31.2% | -3677.4% | 15.5% | 15.5% |
| Return on invested capital (approx.)Operating profit after tax against equity plus debt, less cash. Cash here excludes short-term investments, so this runs low for cash-rich companies. | 0.4% | 48.4% | — | 18.6% | 33.5% |
| P/E ratioPrice paid per dollar of annual profit. | — | 50.91x | 39.30x | 57.46x | 50.91x |
| EV / EBITDA (approx.)Market value plus debt less cash, against operating profit before depreciation. Cash excludes short-term investments, so this runs high for cash-rich companies. | 44.10x | — | — | 36.73x | 36.73x |
| Price to book | 5.36x | 15.89x | -1445.33x | 8.93x | 8.93x |
| Debt to equityTotal liabilities compared with owners' stake. | 1.24x | 1.44x | -158.08x | 0.34x | 0.34x |
| Piotroski F-ScoreNine checks of financial strength. Higher is stronger. | 4/8 | 7/8 | 7/9 | 8/9 | 7.0 |
| Bankruptcy riskAltman Z-Score zone. | grey | safe | safe | safe |
How CRL compares with the others
- CRL's operating margin of 0.6% is lower than the median of the other companies selected (18.8%).
- Its revenue grew more slowly than the median of the other companies selected: -0.9% against 4.0%.
- It has no P/E to set against theirs, because it did not make a profit.
- Its liabilities are higher relative to equity than the median of the other companies selected: 1.2x against 0.3x.
Measured against the other companies entered, from each one's latest annual filing. A difference describes the companies; it does not rank them.